Repurposing cysteamine as a rapdily deployable intervention for COVID-19

重新利用半胱胺作为针对 COVID-19 的快速部署干预措施

• 批准号: 74442
• 金额: $ 124.26万
• 依托单位: NOVABIOTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=74442
• 关键词: Repurposing; cysteamine; rapdily; deployable; intervention

Nylexa is a repurposed therapy, already in advanced development for chest infections in CF patients, that can be rapidly deployed as a treatment for COVID-19\.Nylexa is unique and potentially game-changing, because it has multiple targets; the nSARS-CoV-2 virus, the immune response to the infection and also the complications of intractable bacterial infections secondary to SARS-CoV-2 that result in as many as 20% of COVID-19 deaths currently and more than 50% early in the outbreak (in Hubei Province, China).Nylexa is an antimicrobial-immunomodulator with the potential to alter the trajectory of this disease. To save lives and aid better recovery of those infected with less permanent lung damage. It can be rapidly and safely tested (as an intravenously infused drug) in hospitalised COVID-19 patients in the UK and thereafter, worldwide.Nylexa isn't just great science, it is a truly viable solution to COVID-19: Cost effective, readily available and scalable, such that it can be deployed on the global scale required post successful, expedited clinical testing and approvals. NovaBiotics is perfectly positioned to deliver this outcome as a leading biotechnology company developing first-in-class anti-infective and respiratory disease therapies. The business has a track record of developing novel drug candidates from invention to late stage clinical development and commercialisation thereafter through partnerships with pharmaceutical entities with manufacturing and sales-distribution infrastructure.Nylexa could not only be transformational on outcomes of the COVID-19 pandemic, but for NovaBiotics. Nylexa could potentially become NovaBiotics' first approved drug and could pivot the business to profitability, allowing company growth and re-investment in research and development to advance the company's other, potentially life-saving antimicrobial medicines for bacterial and fungal disease, which could have even greater benefit to society and the economy than Nylexa.

尼乐沙是一种用于治疗CF患者胸部感染的改头换骨疗法，目前已处于后期开发阶段，可迅速用于治疗COVID-19。Nylexa是独一无二的，可能会改变游戏规则，因为它有多个目标；SARS-CoV-2病毒，对感染的免疫反应，以及继发于SARS-CoV-2的难治性细菌感染的并发症，导致目前多达20%的COVID-19死亡人数和疫情早期超过50%的死亡人数（中国湖北省）。耐立沙是一种抗菌素免疫调节剂，有可能改变这种疾病的发展轨迹。挽救生命，帮助那些受感染的人更好地康复，永久性肺损伤较小。它可以在英国和全球范围内的住院COVID-19患者中快速安全地进行测试（作为静脉注射药物）。Nylexa不仅是伟大的科学，而且是COVID-19真正可行的解决方案：具有成本效益，易于获得和可扩展，因此，在成功、快速的临床测试和批准后，它可以在全球范围内部署。作为一家领先的生物技术公司，NovaBiotics完全有能力实现这一目标，开发一流的抗感染和呼吸系统疾病治疗方法。通过与具有生产和销售分销基础设施的制药实体合作，该公司拥有从发明到后期临床开发和商业化的新型候选药物开发记录。尼莱克沙不仅可以改变COVID-19大流行的结果，也可以改变NovaBiotics的结果。Nylexa有可能成为NovaBiotics的第一款获批药物，并将业务转向盈利，使公司得以增长，并在研发方面进行再投资，以推进公司的其他可能挽救生命的细菌和真菌疾病抗菌药物，这些药物对社会和经济的好处可能比Nylexa更大。